Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
ribonucleic acid/brustkrebs
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 48 Ergebnisse
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients with HER2-positive breast cancer who achieve pathologic complete response (pCR) (ypT0/is ypN0) after preoperative therapy with 12 weeks of a taxane, trastuzumab
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine the safety and recommended phase 2 dose (RP2D) of the combination of copanlisib, trastuzumab and pertuzumab in patients with metastatic epidermal growth factor receptor 2 (HER2)-positive breast cancer. (Phase Ib) II. To assess the benefit of adding copanlisib to
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. Prospectively validate a prior germline predictor of paclitaxel-induced peripheral neuropathy (TIPN) using the Common Terminology Criteria for Adverse Events (CTCAE). Specifically, this study will demonstrate that patients with a high-risk TIPN genotype have significantly more
A Breast Cancer Genome Guided Therapy Study
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy.
SECONDARY OBJECTIVES:
I. Assess abemaciclib toxicities. II. To examine the effects of abemaciclib on the
OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Breast cancer management integrating surgery, systemic therapy and radiation therapy tends to systemic treatment as the first therapeutic option, continuing afterwards by surgery and radiation therapy with the scope of decreasing the locoregional treatment. This strategy implies doubts about what
Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
This is an open-label, multi-center, Phase II study of atezolizumab in patients with NSCLC or advanced solid tumors that have had prior treatment with a PD-1 inhibitor (e.g. nivolumab or pembrolizumab). Arm A consists of patients with advanced NSCLC who received first-line PD-1-monotherapy, who have
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To evaluate the safety profile of fulvestrant + abemaciclib + copanlisib hydrochloride (copanlisib) (FAC) and determine the recommended phase 2 dose (RP2D).
II. To determine if FAC is superior to fulvestrant + abemaciclib (FA) using progression-free survival (PFS) as an
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose (RP2D) of ipatasertib plus carboplatin/paclitaxel (arm A), ipatasertib plus carboplatin (arm B), and ipatasertib, atezolizumab, and capecitabine (arm C) in patients with metastatic triple negative breast cancer (TNBC). (Phase I) II.
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine the safety of adding hydroxychloroquine (HCQ) to continuous low dose palbociclib and letrozole and to determine the recommended phase II dose (RP2D) for hydroxychloroquine (HCQ) for the subsequent Phase II study. (Phase I) II. To determine the dose responsiveness
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVE:
I. To evaluate the response rate three months post-conventionally fractionated radiotherapy, relative to baseline, for bone metastases in breast cancer patients receiving concurrent palbociclib and hormone therapy treatment.
SECONDARY OBJECTIVES:
I. To determine whether
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine the safety and tolerability of atezolizumab and idasanutlin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) (Phase I).
II. To determine the anti-tumor effect of atezolizumab and cobimetinib or idasanutlin in patients with ER+ mBC
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic hormone receptor positive (HR+)/HER2 negative (-) breast cancer.
II. To evaluate the safety and tolerability of M7824 and radiation therapy in patients with metastatic
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. Estimate the adherence rate of the experimental exercise program, and deem as feasible if at least 80% of participants complete 80% or more of a 12-week, 180 minute aerobic+resistance training program that combines structured, individualized onsite exercise at the Fred Hutch
Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To correlate levels of histamine in plasma with pain scores in patients with bone metastases from breast cancer that have or have not been treated with palliative radiotherapy.
SECONDARY OBJECTIVES:
I. To perform exploratory studies with additional markers not mentioned,
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Primary Objective and Endpoint To identify decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers.
Secondary Objectives and Endpoints To identify messenger ribonucleic acid (mRNA) gene expression changes following treatment with entinostat, across TNBC.
To evaluate
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
